• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Updated ASCO-NCODA MIP Standards Emphasize Health Equity, Patient-Centered Care, and Integrated Workflows in Oral Oncolytic Management

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Gurjyot K. Doshi, MD, discusses key updates to medically integrated pharmacy standards, which reflect the evolving landscape of oral oncolytic therapy. Read More

A simple genomic score to predict progression of multiple myeloma

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles IVIG treatment significantly boosts platelet counts in pregnant people with thrombocytopenia, revealing key predictors for effective response and optimizing clinical decisions. Read More

NLA: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as...

Novel Agents, Promising Data: The Evolving Landscape of Oncology Care

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

by MM360 Staff | May 30, 2025 | Myeloma News

Source: Pharmacy Times articles Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute...
« Older Entries
Next Entries »

Recent Content

  • WHO grants nonproprietary name to ovarian cancer cell therapy
  • Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases
  • Carvykti label updated to include survival benefit data in myeloma
  • Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis
  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT